Alexza Pharmaceuticals (ALXA +4%) gives back a little but remains firmly in the green following...


Alexza Pharmaceuticals (ALXA +4%) gives back a little but remains firmly in the green following a +7% run-up during the pre-open session on an earlier upgrade from Piper Jaffray to Overweight. Piper notes that it's channel checks with ER physicians, psychiatrists, and opinion leaders was even more encouraging than it expected on both the near and longer-term market potential for Adasuve versus previous projections. Additionally, it's clinical attributes bode well for a value-added partnership being signed soon to enable effective launch in Q3.

Comments (1)
  • Yabadabadoo
    , contributor
    Comments (364) | Send Message
     
    ALXA is an excellent long stock. I own the stock and I am long. If you look at the potential not only of their new drug but the potential of many new drugs as a result of Staccato, ALXA will move to possibly $20 in 2014. I currently have a sell order in at $15 for some of my stock. I have no problem being long on this stock.
    My normal trading pattern is to buy and sell and make the quick profits as I did with the obesity drugs. But ALXA is different. I recommend that all read about this company and listen to their last quarterly results; not only read but listen to the meeting they held. I only recommend to others what I do.
    3 Apr 2013, 11:49 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs